Drug Profile


Alternative Names: AgaDerm; AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaBay Pharmaceuticals
  • Developer Alcon; Galderma; NovaBay Pharmaceuticals
  • Class Alkanesulfonic-acids; Anti-infectives; Antibacterials; Antifungals; Chloramines; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase II/III Impetigo
  • Phase II Catheter infections
  • Preclinical Escherichia coli infections; Klebsiella infections; Onychomycosis
  • No development reported Acne; Staphylococcal infections
  • Discontinued Infectious conjunctivitis; Otorhinolaryngological infections

Most Recent Events

  • 10 Feb 2017 Phase-II development for Catheter infections (Prevention) is ongoing in USA (Instillation, Irrigation)
  • 19 Sep 2016 NovaBay Pharmaceuticals has composition of matter patent protection for Auriclosene in USA up to 2028
  • 19 Sep 2016 Interim adverse events and efficacy data from a phase IIb trial in Catheter infections (Prevention of urinary catheter blockage and encrustation) released by NovaBay Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top